Schott Pharma concluded the first half of the financial year with a revenue of €488.1 million.

The company exceeded its revenue from the previous year by 2.3% at constant currencies.

Its revenue share of high-margin high-value solutions (HVS) rose to 56%, from 55% the year before, and its free cash flow more than doubled to €45.4 million.

The company’s EBITDA stayed almost unchanged at €129.8 million, while its EBITDA margin fell by 0.4%.

Christian Mias, Schott Pharma’s new CEO since May 2026, said: “Schott Pharma developed according to plan in the first half of the year and proved resilient even in a challenging global environment.

“The robustness of our business is rooted in our strategy of consistently focusing on high-margin high-value solutions. On this basis, we confirm our revenue and earnings forecast for the full year.”

Reinhard Mayer, CFO of SCHOTT Pharma, added: “The company is growing profitably. We continue to invest in our capacities to meet the continued high demand for our solutions and advance our technological leadership.

“In addition, we saw a positive development in receivables in the first half of the year, which is reflected in a significant increase in free cash flow and thus a strengthened financial basis.”

Sales

Sales in the Drug Containment Solutions (DCS) segment, which includes glass vials, ampoules and cartridges for the storage of injectable drugs, rose to €286.4 million, an increase of 8.3% at constant currencies.

Continued high demand for sterile cartridges and vials, as well as specialty vials, contributed to the rise in sales.

HVS for the DCS segment accounted for 25% of revenue, an increase of 5% on the previous year.

EBITDA grew by 17.2% to €71.8 million, while the EBITDA margin grew from 22.6% in 2025 to 25.1% in 2026.

The Drug Delivery Systems (DDS) segment, which consists of glass and polymer syringes, reported a decrease in revenue of 5.4%, earning €201.8 million.

The company said this was due to a lower demand for polymer syringes, caused by declining mRNA vaccinations, which could not be fully compensated for by the continued high demand for pre-fillable glass syringes, especially for GLP-1 therapies.

The segment's EBITDA also fell by 18.0% to €59.5 million, while the EBITDA margin decreased by 2.7% to 29.5%.

Cashflow and investments

Cash flow from operating activities totalled €95.1 million, an increase of €22.5 million.

Free cash flow reached €45.4 million, more than doubling the previous year's figure.

The future

Towards the end of 2026, Schott Pharma will launch its new BioPure cartridge.

Equipped with properties to enhance the storage and administration of complex biologics, the product can be integrated into self-administration systems.

The company also expects revenue growth of 2-5% at constant currencies, and an EBITDA margin of around 27%, according to the forecast published in December for the 2026 financial year.

The key figures for Schott Pharma’s Q2 and H1 can be found here.